PofoliaShared via Pofolia

CA A Cancer Journal for Clinicians· 2023Q1

Cancer statistics, 2023

Rebecca L. Siegel, Kimberly D. Miller, Nikita Sandeep Wagle, Ahmedin Jemal

Short summary

In 2023, the US is projected to see 1.96 million new cancer cases and 610,000 deaths, with notable incidence increases in prostate, breast, uterine corpus, liver cancers, and melanoma. Despite these rises, the overall cancer death rate continued its decline, falling 1.5% from 2019 to 2020, contributing to 3.8 million deaths averted since 1991.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Projected 1,958,310 new cancer cases and 609,820 deaths in the US for 2023.
  • Incidence is increasing for prostate (3% annually), breast, uterine corpus, liver cancers, and melanoma.
  • Overall cancer death rate declined 1.5% from 2019-2020, contributing to 3.8 million deaths averted since 1991.
  • Cervical cancer incidence dropped 65% in young women (early 20s) due to HPV vaccination, predicting future declines in HPV-related cancers.

AI-generated from the title and abstract; the full text is not read.

Abstract

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries and mortality data collected by the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, translating to an additional 99,000 new cases; otherwise, however, incidence trends were more favorable in men compared to women. For example, lung cancer in women decreased at one half the pace of men (1.1% vs. 2.6% annually) from 2015 through 2019, and breast and uterine corpus cancers continued to increase, as did liver cancer and melanoma, both of which stabilized in men aged 50 years and older and declined in younger men. However, a 65% drop in cervical cancer incidence during 2012 through 2019 among women in their early 20s, the first cohort to receive the human papillomavirus vaccine, foreshadows steep reductions in the burden of human papillomavirus-associated cancers, the majority of which occur in women. Despite the pandemic, and in contrast with other leading causes of death, the cancer death rate continued to decline from 2019 to 2020 (by 1.5%), contributing to a 33% overall reduction since 1991 and an estimated 3.8 million deaths averted. This progress increasingly reflects advances in treatment, which are particularly evident in the rapid declines in mortality (approximately 2% annually during 2016 through 2020) for leukemia, melanoma, and kidney cancer, despite stable/increasing incidence, and accelerated declines for lung cancer. In summary, although cancer mortality rates continue to decline, future progress may be attenuated by rising incidence for breast, prostate, and uterine corpus cancers, which also happen to have the largest racial disparities in mortality.

The authors' abstract, as published at the source. CA A Cancer Journal for Clinicians, 2023 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Oncology

OncologyMedicine